Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.
Status:
Recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
Patients diagnosed with locally advanced nasopharyngeal carcinoma will be recruited in this
study. All the patients will get 3 cycles of GP+ Envafolimab for the induction chemotherapy.
After that, the patients will receive concurrent chemoradiotherapy. Radiotherapy will be
given by IMRT, under the dose of GTVnx 68-70Gy/30-33f, 5d/w,6-7w, during which, every patient
would receive 2 cycles of DDP+Envafolimab as concurrent chemotherapy. Then patients would
receive Envafolimab every 3 weeks for maintenance treatment for a year, until disease
progression or intolerance of treatment. . We aim to evaluate the three years progression
free survival of these patients by the combination of Envafolimab with curative
chemoradiotherapy.